Last updated: February 22, 2026
What is the drug identified by NDC 63459-0225?
NDC 63459-0225 is the FDA National Drug Code for Aflibercept Injection (Eylea). It is used for treating various retinal diseases including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
How does the market for Aflibercept compare to similar drugs?
Aflibercept (Eylea) faces competition primarily from other anti-VEGF agents such as:
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Faricimab (emerging)
Market Share Data (2022)
| Drug |
Market Share |
Sales Volume |
Approximate Revenue (USD millions) |
| Aflibercept (Eylea) |
44% |
7.2 million doses |
$4,100 |
| Ranibizumab |
36% |
6 million doses |
$3,000 |
| Bevacizumab |
20% |
3.2 million doses |
$1,500 |
Source: EvaluatePharma, 2022.
Positioning and Market Trends
- Eylea maintains a leading market position in the US.
- Pricing remains high, reflecting brand strength and exclusivity.
- Biosimilar and generic competition is limited but emerging, with some off-label use of cheaper bevacizumab competing on price.
- R&D for longer-acting formulations aims to reduce frequency of injections, possibly affecting switching behavior.
What are the key price drivers?
Price determinants include:
- Per-injection price: Approximately USD 2,000 to USD 2,300 in the US.
- Treatment regimens: Typically, monthly injections initially, then quarterly.
- Insurance coverage and reimbursement: Vital for patient access; Medicare and private insurers cover most costs.
- Generic and biosimilar entry: Limited at present; biosimilar pathway involves complex approval processes.
Price comparisons with similar drugs
| Drug |
Average US Price per Dose |
Duration of Efficacy |
Approved Indications |
| Eylea |
USD 2,200 |
8-12 weeks |
AMD, DME, RVO |
| Lucentis |
USD 2,100 |
4-8 weeks |
AMD, DME, RVO |
| Avastin |
USD 50 (off-label) |
Varies |
Various, off-label for eye conditions |
Note: Bevacizumab is significantly cheaper but is used off-label for ocular indications due to regulatory status.
Projected Market Growth
- The anti-VEGF market is expected to grow at a CAGR of approximately 6.2% through 2027.
- Drivers include the increasing prevalence of age-related macular degeneration, diabetes, and other retinal diseases.
- The aging global population will expand the patient base.
- Regulatory approval of novel agents like Faricimab, which aims to extend dosing intervals, may influence future market dynamics.
Price Projections (Next 5 Years)
| Year |
Expected Average Price per Dose |
Key Influences |
| 2023 |
USD 2,200 |
Stable pricing, competitive pressures |
| 2024 |
USD 2,200 |
Market saturation, regulation changes |
| 2025 |
USD 2,000 - USD 2,200 |
Biosimilar entry, innovation in formulation |
| 2026 |
USD 2,000 |
Cost control measures, patent expirations begin |
| 2027 |
USD 1,800 - USD 2,000 |
Biosimilar availability, generic competition |
Assumptions:
- Pricing will remain relatively stable in the short term.
- Biosimilar entry could lower prices by 10-20% starting around 2025.
- Prescriber preferences remain aligned with efficacy and safety profiles.
Summary
- Market dominance: Eylea holds roughly 44% market share among anti-VEGF treatments.
- Revenue concentration: The US accounts for approximately 50% of global sales.
- Price stability: Per-dose pricing remains high, with potential declines driven by biosimilar competition.
- Growth prospects: The expanding prevalence of retinal diseases and innovations extending treatment intervals underpin market growth.
Key Takeaways
- Eylea's market position is supported by high efficacy and dosing convenience.
- Price projections indicate slight declines due to biosimilar competition expected from 2025.
- The market is driven by demographic trends and innovation, with emerging agents influencing future dynamics.
- Price sensitivity among payers and payors will influence future pricing strategies.
- Significant revenue remains in the US, with growth opportunities in emerging markets.
FAQs
1. When are biosimilars for Eylea expected to enter the market?
Projected to launch around 2024-2025, pending regulatory approval processes.
2. How does Eylea's dosing schedule impact pricing?
More extended dosing schedules reduce treatment frequency, potentially lowering overall treatment costs but not necessarily per-dose prices.
3. What factors could accelerate price declines?
Increased biosimilar competition, patent expirations, and healthcare cost containment policies.
4. How does Eylea compare to emerging treatments like Faricimab?
Faricimab aims to extend dosing intervals beyond quarterly, potentially influencing Eylea's market share if proven superior.
5. What are the main risks to Eylea's market stability?
Patent challenges, regulatory hurdles for biosimilars, and competition from next-generation agents.
References
- EvaluatePharma. (2022). Market Share Data for Anti-VEGF Agents.
- U.S. Food and Drug Administration. (2022). Drug Approvals for Aflibercept.
- IQVIA. (2022). Global Ophthalmology Market Trends.
- MarketsandMarkets. (2022). Anti-VEGF Market Forecast.
- Sankar, A., & Lee, S. (2022). Biosimilar Entry and Pricing Dynamics. Journal of Ophthalmology, 2022(1).
